


Threats to the CD20 space - and Biogen's cash cow



Amy Brown

Biogen has collected billions in royalties from Roche's anti-CD20 franchise, and will continue to do so [after opting in to a bispecific project this week](#). But what are the threats to this income stream, and for how much longer can Roche expect to dominate this space? Consensus forecasts from *Evaluate Pharma* show why Biogen decided to claim its rights over mosunetuzumab. The project is attracting the highest sales forecasts among the next-generation CD20 approaches, though there are [many contenders in the pipeline](#) and lots of data still to come. Abbvie this week said it hoped to file the Genmab-derived epcoritamab for accelerated approval later this year, for example, putting it not too far behind Roche, which has started a rolling submission for mosunetuzumab. Elsewhere, biosimilar versions of Rituxan are already biting; the market share of products from Pfizer and Teva/Celltrion are not too far off Rituxan's slice of the US market. Ocrevus is making up those losses for now, and the MAb is unlikely to see low-cost competition this decade. But Roche will be highly motivated to ensure that CD20 bispecifics prolong its stranglehold on this space, a determination from which Biogen looks well set to benefit.

Roche has long dominated the anti-CD20 space (actual and forecast data)



Evaluate Pharma

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas
[+1-617-573-9450](tel:+16175739450)

Evaluate APAC
[+81-\(0\)80-1164-4754](tel:+8108011644754)

© Copyright 2022 Evaluate Ltd.